Provectus Biopharmaceuticals (PVCT) 10-Q 13 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 11, 2020
Document And Entity Information
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		390,689,475
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 213,739	$ 590,706
Short-term receivables - legal fees, settlement and other, net	74,235	55,058
Prepaid expenses	240,361	350,249
Total Current Assets	528,335	996,013
Equipment and furnishings, less accumulated depreciation of $68,153 and $64,630, respectively	54,861	58,384
Operating lease right-of-use asset	176,439	194,400
Patents, net of accumulated amortization of $11,655,118 and $11,487,338, respectively	60,327	228,107
Total Assets	819,962	1,476,904
Current Liabilities:
Accounts payable - trade	1,581,762	1,125,890
Accrued interest	75,333	65,333
Convertible notes payable	1,000,000	500,000
Other accrued expenses	1,250,227	1,255,266
Current portion of operating lease liability	79,533	76,423
Total Current Liabilities	3,986,855	3,022,912
Accrued interest	1,763,304	1,501,864
Accrued interest - related parties	1,360,293	1,226,582
Convertible notes payable	12,697,000	12,997,000
Convertible notes payable - related parties	6,770,000	6,670,000
Non-current portion of operating lease liability	108,070	130,658
Total Liabilities	26,685,522	25,549,016
Commitments and contingencies (Note 9)
Stockholders' Deficiency:
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at March 31, 2020 and December 31, 2019; aggregate liquidation preference of $3,500 at March 31, 2020 and December 31, 2019
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 390,689,475 and 389,889,475 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	390,689	389,889
Additional paid-in capital	209,420,675	209,378,835
Accumulated other comprehensive loss	(33,035)	(24,008)
Accumulated deficit	(235,643,889)	(233,816,828)
Total Stockholders' Deficiency	(25,865,560)	(24,072,112)
Total Liabilities and Stockholders' Deficiency	$ 819,962	$ 1,476,904

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Accumulated depreciation on equipment and furnishings	$ 68,153	$ 64,630
Accumulated amortization on patents	$ 11,655,118	$ 11,487,338
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Aggregate liquidation preference	$ 3,500	$ 3,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	390,689,475	389,889,475
Common stock, shares outstanding	390,689,475	389,889,475
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating Expenses:
Research and development	$ 909,446	$ 1,037,331
General and administrative	538,794	759,253
Total Operating Expenses	1,448,240	1,796,584
Total Operating Loss	(1,448,240)	(1,796,584)
Other Income/(Expense):
Gain on settlement of lawsuits		675,000
Research and development tax credit	26,251	84,072
Investment and interest income	79	2,255
Interest expense	(405,151)	(334,573)
Total Other Income/(Expense)	(378,821)	426,754
Net Loss	$ (1,827,061)	$ (1,369,830)
Basic and Diluted Loss Per Common Share	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	390,557,607	384,705,639

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Net Loss	$ (1,827,061)	$ (1,369,830)
Other Comprehensive Loss:
Foreign currency translation adjustments	(9,027)	(22,363)
Total Comprehensive Loss	$ (1,836,088)	$ (1,392,193)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Preferred Stock Series B [Member]
Beginning Balance
Beginning Balance, shares	100	100
Common stock issued upon exercise of warrants
Common stock issued upon exercise of warrants, shares
Net loss
Other comprehensive loss
Ending Balance
Ending Balance, shares	100	100
Common Stock [Member]
Beginning Balance	$ 389,889	$ 384,615
Beginning Balance, shares	389,889,475	384,614,528
Common stock issued upon exercise of warrants	$ 800	$ 100
Common stock issued upon exercise of warrants, shares	800,000	100,000
Net loss
Other comprehensive loss
Ending Balance	$ 390,689	$ 384,715
Ending Balance, shares	390,689,475	384,714,528
Additional Paid-In Capital [Member]
Beginning Balance	$ 209,378,835	$ 209,092,187
Common stock issued upon exercise of warrants	41,840	5,230
Net loss
Other comprehensive loss
Ending Balance	209,420,675	209,097,417
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(24,008)
Common stock issued upon exercise of warrants
Net loss
Other comprehensive loss	(9,027)	(22,363)
Ending Balance	(33,035)	(22,363)
Accumulated Deficit [Member]
Beginning Balance	(233,816,828)	(226,894,291)
Common stock issued upon exercise of warrants
Net loss	(1,827,061)	(1,369,830)
Other comprehensive loss
Ending Balance	(235,643,889)	(228,264,121)
Beginning Balance	(24,072,112)	(17,417,489)
Common stock issued upon exercise of warrants	42,640	5,330
Net loss	(1,827,061)	(1,369,830)
Other comprehensive loss	(9,027)	(22,363)
Ending Balance	$ (25,865,560)	$ (18,804,352)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows From Operating Activities:
Net loss	$ (1,827,061)	$ (1,369,830)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		2,650
Noncash lease expense	17,961
Depreciation	3,523	21,311
Amortization of patents	167,780	167,780
Changes in operating assets and liabilities
Short term receivables	(27,728)	(33,943)
Prepaid expenses	109,888	98,225
Accounts payable - trade	456,437	(1,857,444)
Other accrued expenses	(2,795)	570,624
Operating lease liability	(19,478)
Accrued interest expense	405,151	334,574
Net Cash Used In Operating Activities	(716,322)	(2,066,053)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	200,000	3,775,000
Proceeds from issuance of convertible notes payable - related parties	100,000	25,000
Proceeds from exercise of warrants	42,640	5,330
Net Cash Provided By Financing Activities	342,640	3,805,330
Effect of Exchange Rate Changes on Cash	(3,285)	(22,363)
Net (Decrease) Increase In Cash and Cash Equivalents	(376,967)	1,716,914
Cash and Cash Equivalents, Beginning of Period	590,706	50,986
Cash and Cash Equivalents, End of Period	213,739	1,767,900
Non-cash investing and financing activities:
Offset of related party receivable and payable		$ 25,000

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company that is developing a new class of drugs for oncology, hematology, and dermatology based on an entire, wholly-owned, family of small molecules called halogenated xanthenes: ● Oncology: PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma). Orphan drug designation status has been granted to PV-10 by the FDA for neuroblastoma in 2018. ● Hematology. ● Dermatology: To date, the Company has not generated any revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2019 filed with the SEC on March 5, 2020. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. A novel strain of coronavirus (“CoV”), severe acute respiratory syndrome (“SARS”) CoV 2 The full extent of SARS-CoV-2 future impacts on the Company’s operations and financial condition is uncertain. A prolonged SARS-CoV-2 outbreak could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development.

Liquidity and Going Concern

Liquidity and Going Concern	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s cash and cash equivalents were $213,739 at March 31, 2020. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10, PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital. The Company plans to access capital resources through possible public or private equity offerings, including the 2020 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2020 Financing or otherwise, it will not be able to pay its obligations as they become due. Subsequent to March 31, 2020, the Company received an aggregate $50,000 in connection with the 2020 Financing. In April 2020, the Company received $62,500 from the Paycheck Protection Program (“PPP”) and $3,000 from an Economic Injury Disaster Loan (“EIDL”) grant (“EIDG”) of the Coronavirus Aid, Relief, and Economic Security Act (The “CARES Act”). See Note 10 – Subsequent Events. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure you that it will be successful in developing further, co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug products of the Company, or entering into any commercial financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2020 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2020 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot assure you that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Critical Accounting Policies

Critical Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Critical Accounting Policies	3. Critical Accounting Policies Since the date the Company’s December 31, 2019 consolidated financial statements were issued in its 2019 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below. Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board (‘FASB”) issued Accounting Standards Update (“ASU”) No. 2020-03, Codification Improvements to Financial Instruments. There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s financial statements. The Company adopted certain provisions which have become effective during fiscal 2020 within ASU 2020-03 and its adoption did not have a material impact on the Company’s condensed consolidated financial statements and financial statement disclosures. The Company is currently evaluating the effect that adopting the remaining new accounting guidance will have on its condensed consolidated financial statements and related disclosures. The CARES Act On March 27, 2020, President Trump signed the CARES Act into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. Under ASC 740 of GAAP, the effects of new legislation are recognized upon enactment. Accordingly, the CARES Act is effective beginning in the quarter ended March 31, 2020. The adoption of the CARES Act provisions did not have a material impact on the Company’s condensed consolidated financial statements.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	4. Convertible Notes Payable 2020 Financing On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $20,000,000 (the “2020 Financing”). Subject to the terms and conditions of the 2020 Term Sheet, the Company will use its best efforts to arrange for the 2020 Financing, which amounts will be obtained in several tranches. The proceeds from the 2020 Financing will be used to fund the Company’s clinical development program, as currently constituted and envisioned, and to fund the Company’s general and administrative expenses. Since financing was launched and through March 31, 2020, the Company had received aggregate Loans of $400,000 in connection with the 2020 Financing. The Series D Preferred Stock As of March 31, 2020, and through the date of filing, the Series D Preferred Stock had not been designated by the Board. Per the terms of the notes issued in connection with the 2017 and 2020 Financings, if the Company has not designated the Series D Preferred Stock or if an insufficient number of Series D Preferred shares exist upon a conversion by a note holder, then the outstanding loans will continue to accrue interest at a rate of 8% per annum until which time the Company has designated a sufficient number of Series D Preferred shares. As a result, the Company did not analyze the notes for a potential beneficial conversion feature as the definition of a firm commitment has not been met since the notes were not convertible as of their respective dates of issuance or as of March 31, 2020. Convertible Notes Payable – Related Parties During the three months ended March 31, 2020, the Company entered into additional related party 2020 Notes in the aggregate principal amount of $100,000. Convertible Notes Payable – Non-Related Parties During the three months ended March 31, 2020, the Company entered into additional non-related party 2020 Notes in the aggregate principal amount of $200,000. As of March 31, 2020, the Company had borrowed $300,000 under these notes.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions During the three months ended March 31, 2020 and 2019, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $52,400 and $110,000, respectively, for services rendered. Accrued director fees for Mr. Horowitz as of March 31, 2020 and 2019 were $18,750 and $18,750, respectively. Mr. Horowitz serves as both COO and a Director. See Note 4 and Note 6 for details of other related party transactions.

Receivables

Receivables	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Receivables	6. Receivables The following table summarizes the receivables at March 31, 2020 and December 31, 2019: March 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 74,235 $ - $ - $ 74,235 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 74,235 $ - $ - $ 74,235 December 31, 2019 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 55,058 $ - $ - $ 55,058 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 55,058 $ - $ - $ 55,058

Stockholders' Deficiency

Stockholders' Deficiency	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Deficiency	7. Stockholders’ Deficiency Common Stock During the three months ended March 31, 2020, warrant holders exercised warrants to purchase an aggregate of 800,000 shares of common stock at a price of $0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $42,640.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	8. Leases The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022. Payments range from approximately $7,300 to $7,800 per month. Total operating lease expense for the three months ended March 31, 2020 was $21,302, of which, $14,201 was included within research and development and $7,101 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the three months ended March 31, 2019 was $34,806, of which, $23,204 was included within research and development and $11,602 was included within general and administrative expenses on the condensed consolidated statement of operations. As of March 31, 2020, the Company had no leases that were classified as a financing lease. As of March 31, 2020, the Company did not have additional operating and financing leases that have not yet commenced.  A summary of the Company’s right-of-use assets and liabilities is as follows: Three Months Ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 22,441 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - Weighted Average Remaining Lease Term Operating leases 2.25 Years Weighted Average Discount Rate Operating leases 8.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of March 31, 2020 were as follows: Years Amount 2020 68,225 2021 92,471 2022 46,688 Total future minimum lease payments 207,384 Less: amount representing imputed interest (19,781 ) Total $ 187,603

Commitments, Contingencies and

Commitments, Contingencies and Litigation	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	9. Commitments, Contingencies and Litigation Culpepper Travel Expenses and Related Collection Efforts On December 27, 2016, the then-Board of Directors (the “then-Board”) unanimously voted to terminate then-interim Chief Executive Officer, then-Chief Operating Officer, and former Chief Financial Officer, Peter Culpepper (“Culpepper”), effective immediately, from all positions he held with the Company and each of its subsidiaries, “for cause,” in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”), based on the results of the investigation conducted by the Audit Committee of the then-Board regarding improper expense reimbursements to Culpepper. The Company took the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Stipulated Settlement Agreement and Mutual Release in the Kleba Derivative Lawsuit Settlement (the “Derivative Lawsuit Settlement”) such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper’s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,104,543 as of March 31, 2020 and December 31, 2019, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount. Culpepper disputed that he was terminated “for cause” under the Culpepper Employment Agreement. Pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute on June 28, 2017. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating both Culpepper’s claim for severance against the Company and the Company’s claims against Culpepper for improper expense reimbursements and amounts Culpepper owes the Company under the Derivative Lawsuit Settlement (the “Culpepper Arbitration”). On September 12, 2018, the arbitrator issued his final award in favor of the Company. On October 4, 2018, the Company filed a petition with the Chancery Court for Davidson County, Tennessee to confirm the arbitration award. This court entered an order confirming the arbitrator’s award on January 23, 2019. On February 20, 2019, Culpepper filed a motion to alter or amend this judgment. On March 22, 2019, the Chancery Court upheld the arbitration award in favor of the Company. On April 16, 2019, Culpepper filed a Notice of Appeal with the Tennessee Court of Appeals regarding the Chancery Court’s judgment. The Company and Culpepper submitted their respective court of appeal briefs on November 12, 2019 and December 3, 2019, respectively. Oral arguments were held on January 7, 2020. On April 14, 2020, the Court of Appeals affirmed the Chancery Court’s judgement and awarded court costs to the Company. The time for Culpepper to file an application for permission to appeal to the Tennessee Supreme Court runs sixty (60) days from the ruling of the Court of Appeals.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events Convertible Notes Payable Subsequent to March 31, 2020, the Company entered into 2020 Notes with non-related parties in the aggregate principal amount of $50,000 in connection with 2 nd Paycheck Protection Program On April 20, 2020, the Company received $62,500 from the CARES Act PPP. The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times their average monthly payroll expenses. The loan principal and accrued interest are forgivable, as long as the borrower uses loan proceeds for eligible purposes during the eight weeks following disbursement, such as payroll, benefits, rent, and utilities, and maintains its payroll levels. The amount of loan forgiveness is reduced if the borrower terminates employees or reduces salaries during this eight-week period, subject to certain qualifications and exclusions. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first seven months. The Company intends to use PPP proceeds it received for purposes consistent with PPP criteria. While the Company currently believes its use of PPP loan proceeds should meet the conditions for forgiveness of the loan, we cannot assure you that we will not take actions that may cause the Company to be ineligible for loan forgiveness in whole or in part or that PPP eligibility requirements may not change that would result in making the Company or the Company’s use of the PPP proceeds ineligible. Economic Injury Disaster Grant On April 29, 2020, the Company received $3,000 from the CARES Act EIDL. In response to the SARS-CoV-2 pandemic, businesses could apply for an EIDL advance, which is designed to provide economic relief to businesses currently experiencing a temporary loss. EIDL advances do not have to be repaid.

Critical Accounting Policies (P

Critical Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board (‘FASB”) issued Accounting Standards Update (“ASU”) No. 2020-03, Codification Improvements to Financial Instruments. There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s financial statements. The Company adopted certain provisions which have become effective during fiscal 2020 within ASU 2020-03 and its adoption did not have a material impact on the Company’s condensed consolidated financial statements and financial statement disclosures. The Company is currently evaluating the effect that adopting the remaining new accounting guidance will have on its condensed consolidated financial statements and related disclosures. The CARES Act On March 27, 2020, President Trump signed the CARES Act into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. Under ASC 740 of GAAP, the effects of new legislation are recognized upon enactment. Accordingly, the CARES Act is effective beginning in the quarter ended March 31, 2020. The adoption of the CARES Act provisions did not have a material impact on the Company’s condensed consolidated financial statements.

Receivables (Tables)

Receivables (Tables)	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Summary of Receivables	The following table summarizes the receivables at March 31, 2020 and December 31, 2019: March 31, 2020 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 74,235 $ - $ - $ 74,235 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 74,235 $ - $ - $ 74,235 December 31, 2019 Tax Credit Legal Fees Settlement Total Provectus Australia Tax Credit $ 55,058 $ - $ - $ 55,058 Gross receivable - 455,500 1,649,043 2,104,543 Reserve for uncollectibility - (455,500 ) (1,649,043 ) (2,104,543 ) Net receivable $ 55,058 $ - $ - $ 55,058

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Three Months Ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 22,441 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - Weighted Average Remaining Lease Term Operating leases 2.25 Years Weighted Average Discount Rate Operating leases 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of March 31, 2020 were as follows: Years Amount 2020 68,225 2021 92,471 2022 46,688 Total future minimum lease payments 207,384 Less: amount representing imputed interest (19,781 ) Total $ 187,603

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	May 12, 2020	Apr. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Cash and cash equivalents			$ 213,739	$ 590,706
Subsequent Event [Member]
Loans received in connection with financing	$ 50,000
Subsequent Event [Member] | Paycheck Protection Program [Member] | The CARES Act [Member]
Loans received in connection with financing		$ 62,500
Subsequent Event [Member] | Economic Injury Disaster Loan [Member]
Loans received in connection with financing		$ 3,000

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Borrowed outstanding convertible notes payable	$ 1,000,000	$ 500,000
2020 Notes [Member] | Non-Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount	200,000
Borrowed outstanding convertible notes payable	300,000
2020 Notes [Member] | Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount	100,000
2020 Financing [Member]
Related Party Transaction [Line Items]
Proceeds from secured convertible loans	$ 400,000
2020 Financing [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount		$ 20,000,000
2017 and 2020 Financings [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Interest rate	8.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Mr Bruce Horowitz [Member] - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Consulting fees	$ 52,400	$ 110,000
Accrued director fees	$ 18,750	$ 18,750

Receivables - Summary of Receiv

Receivables - Summary of Receivables (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Tax credit	$ 74,235	$ 55,058
Gross receivable	2,104,543	2,104,543
Reserve for uncollectibility	(2,104,543)	(2,104,543)
Net receivable	74,235	55,058
Legal Fees [Member]
Tax credit
Gross receivable	455,500	455,500
Reserve for uncollectibility	(455,500)	(455,500)
Net receivable
Settlement [Member]
Tax credit
Gross receivable	1,649,043	1,649,043
Reserve for uncollectibility	(1,649,043)	(1,649,043)
Net receivable
Provectus Australia [Member]
Tax credit	74,235	55,058
Gross receivable
Reserve for uncollectibility
Net receivable	$ 74,235	$ 55,058

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - Warrant Holders [Member]	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Class of Stock [Line Items]
Warrant to purchase common stock | shares	800,000
Warrant exercise price | $ / shares	$ 0.0533
Aggregate cash proceeds | $	$ 42,640

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended
	Mar. 31, 2020USD ($)ft²	Mar. 31, 2019USD ($)
Leases payments, per month	$ 22,441
Lease expense	21,302	$ 34,806
Research and Development Expense [Member]
Lease expense	14,201	23,204
General and Administrative Expense [Member]
Lease expense	$ 7,101	$ 11,602
Knoxville, Tennessee [Member]
Area of land | ft²	4,500
Lease term	5 years
Lease expiration date	Jun. 30, 2022
Knoxville, Tennessee [Member] | Minimum [Member]
Leases payments, per month	$ 7,300
Knoxville, Tennessee [Member] | Maximum [Member]
Leases payments, per month	$ 7,800

Leases - Schedule of Right-of-u

Leases - Schedule of Right-of-use Assets and Liabilities (Details)	3 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 22,441
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Weighted Average Remaining Lease Term: Operating leases	2 years 2 months 30 days
Weighted Average Discount Rate: Operating leases	8.00%

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Mar. 31, 2020USD ($)
Leases [Abstract]
2020	$ 68,225
2021	92,471
2022	46,688
Total future minimum lease payments	207,384
Less: amount representing imputed interest	(19,781)
Total	$ 187,603

Commitments, Contingencies an_2

Commitments, Contingencies and Litigation (Details Narrative) - Culpepper Employment Agreement [Member] - Peter Culpepper [Member] - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Damages sought to be receivable	$ 2,240,000
Litigation cost	227,750
Litigation reserve	$ 2,104,543	$ 2,104,543

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	May 12, 2020	Apr. 30, 2020	Apr. 20, 2020	Mar. 31, 2020
2020 Notes [Member] | Non-Related Party [Member]
Debt instrument, face amount				$ 200,000
Subsequent Event [Member]
Loans received in connection with financing	$ 50,000
Subsequent Event [Member] | Paycheck Protection Program [Member] | The CARES Act [Member]
Loans received in connection with financing		$ 62,500
Loan description		The PPP provides for loans qualifying businesses for amounts of up to 2.5 times their average monthly payroll expenses.
Loan term		2 years
Loan interest rate			1.00%
Subsequent Event [Member] | Economic Injury Disaster Loan [Member]
Loans received in connection with financing		$ 3,000
Subsequent Event [Member] | 2020 Notes [Member] | Non-Related Party [Member]
Debt instrument, face amount	$ 50,000